Financial Services
Live Price
Offline$0.98
+7.99% today
1Y Change
+4.68%
Window
Jun 30, 2025 โ Jun 17, 2026
Coverage: 14 bars ยท Jun 30, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioPharma Credit PLC (BOPCF) is a Financial Services stock with a market cap of $1.06B. The stock last traded around $0.98 and up 4.7% across the available one-year price window (Jun 30, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +12.7%, EPS growth of +10.0%, a dividend yield of 10.5%. What stands out right now is revenue +12.7%, EPS +10.0%, free cash flow -18.6% with operating margin 92.5% and ROIC 11.2%. The dividend matters to the case here, with a current yield around 10.5%. Valuation is more restrained than many high-expectation growth names at P/E 8.2 and price/sales 7.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines BOPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.7% vs +3.4% peer median
Operating Margin
Above sector median
+92.5% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +12.7% and EPS at +10.0%, with operating margin around 92.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 10.5%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BOPCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BOPCF Max Drawdown
-11.03%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BOPCF and SPY.
Company Overview
BioPharma Credit PLC
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.